Search
Powered By HealthLine
Health Tools
 Mood Tracker
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Study Reports Progress Against Fatal Brain Cancer

In mice, researchers discover new way to prevent recurrence of glioblastoma


Related Encyclopedia
 border=
Acoustic Neurinoma
Adenocarcinoma of the Lung and Brain Metastases
Basal Cell Carcinoma
Bell's Palsy
More...

Related Healthscout Videos
 border=
Cracking the Code: Pompe Disease
Early Detection of Pancreatic Cancer: Medicine's Next Big Thing?
Botox for Parkinsons
Beating Heart Surgery
More...

Related Animations
 border=
Breast Self-Exam Video
Colon Cancer
More...

Related Drug Information
 border=
Adderal XR
Concerta
Coumadin
Depakote
More...

Related News Articles
 border=
Healthier Lifestyles May Prevent 340,000 U.S. Cancers a Year: Study
Bilingual People More Adept at Learning Third Language
Breast Cancer Treatment May Lead to Hip Fracture
Cancer on the Rise in Developing Countries: Report
More...

WEDNESDAY, Feb. 24 (HealthDay News) -- A new method to prevent recurrence of deadly glioblastoma brain cancer shows promise, say U.S. scientists.

Radiation can temporarily shrink a glioblastoma tumor, but the cancer nearly always recurs within weeks or months. Few people with this type of brain cancer survive more than two years after diagnosis.

Text Continues Below



In a study on mice, Stanford University School of Medicine researchers found that blocking access to oxygen and nutrients prevents tumor recurrence.

The first step, they said, was discovering that tumors blasted with radiation use a secondary pathway to generate blood vessels needed for regrowth.

"Under normal circumstances, this pathway is not important for growth of most tumors," senior author Martin Brown, a professor of radiology, said in a Stanford news release. "What we hadn't realized until recently is that radiation meant to kill the cancer cells also destroys the existing blood vessels that nourish the tumor. As a result, it has to rely on a backup blood delivery pathway."

The Stanford team used a molecule called AMD3100 to block the secondary glioblastoma tumor growth process in mice.

The study was published online Feb. 22 in the Journal of Clinical Investigation.

AMD3100 is already approved for different uses in humans so it's possible that clinical trials to test the molecule in glioblastoma patients could take place soon, according to the researchers. However, any routine use of AMD3100 or similar molecules to treat glioblastoma is likely still years away, they added.

In their study, the Stanford team focused on glioblastoma, but other tumors use a similar secondary blood delivery pathway to survive radiation treatment.

More information

The U.S. National Cancer Institute has more about brain tumors.



-- Robert Preidt

Copyright © 2010 HealthDay. All rights reserved.
Last updated 2/24/2010

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates




SOURCE: Stanford University, news release, Feb. 22, 2010


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2011. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire